ArticleBMC gastroenterology2026
Single-cell and bulk transcriptomics identify senescence-related EMT transcriptional programs and a prognostic framework in pancreatic ductal adenocarcinoma.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundSenescence-related transcriptional programs and epithelial-mesenchymal transition (EMT) are implicated in pancreatic ductal adenocarcinoma (PDAC) progression and therapy resistance. However, the single-cell distribution, functional heterogeneity, and clinical relevance of EMT-associated senescence-like programs remain incompletely defined.
methodsWe integrated single-cell RNA sequencing (scRNA-seq) data from 10 treatment-naive PDAC tumors with bulk transcriptomic profiles from TCGA-PAAD and an independent validation cohort. Senescence-related transcriptional activity was estimated using ssGSEA based on a curated CellAge gene set. EMT-like tumor cell subclusters were identified by unsupervised clustering after marker-based annotation, and differentiation trajectories were reconstructed using pseudotemporal analysis. A senescence-related gene signature was established for molecular subtyping and prognostic modeling. Drug sensitivity was explored using GDSC-based prediction and connectivity mapping.
resultsscRNA-seq analysis suggested that EMT-like tumor cells carried relatively high senescence-related transcriptional scores within the PDAC tumor microenvironment. Subclustering revealed five distinct EMT-like subsets, among which KRT19⁺ and UBE2C⁺ subsets showed high senescence-related scores, VMP1⁺ and NFE4⁺ subsets showed intermediate scores, and the MZB1⁺ subset showed low scores. Pseudotemporal ordering suggested an association between senescence-related transcriptional activity and EMT-like progression, but did not establish causality. Twelve senescence-related genes stratified patients into two subtypes (SubA and SubB). SubB patients exhibited poorer overall survival (median OS 17.0 vs. 34.8 months, log-rank P = 0.04) and an immune-excluded phenotype characterized by CD8 + T-cell depletion and reduced stromal/immune scores, despite evidence of altered tumor antigenicity. A refined 5-gene risk score (CDK1, FOXM1, NDRG1, PAK4, TPX2) showed moderate prognostic performance. Experimental validation supported up-regulation trends for the five model genes in PDAC, with statistically significant overexpression observed for NDRG1, PAK4, and TPX2 in the small validation cohort. TPX2 expression was positively associated with P16 expression. UMAP-based mapping revealed subcluster-specific enrichment of model genes. Drug-response prediction revealed distinct predicted IC₅₀ profiles between high- and low-risk patients, while CMap analysis nominated negatively connected compounds that may reverse the high-risk transcriptional signature.
conclusionsEMT-like tumor subclusters with elevated senescence-related transcriptional activity may be associated with PDAC aggressiveness and therapy-related phenotypes. The molecular subtypes and 5-gene signature provide a hypothesis-generating framework for prognosis prediction and therapy selection. Prospective validation and functional experiments are required before clinical application or senescence-targeted treatment recommendations can be made.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.